Search Results - "Schneiders, Famke"

Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials by Senan, Suresh, Schneiders, Famke L., Moghanaki, Drew

“…The findings of two well conducted trials that randomised 1803 patients with a peripheral non-small cell lung cancer measuring ≤ 2 cm to a lobar to sub-lobar…”
Get full text

Finding the Goldilocks zone in neoadjuvant radioimmunotherapy by Schneiders, Famke L., Senan, Suresh

“…Advances in cancer immunotherapy have led to clinical trials of immunotherapy-based neoadjuvant treatments for early stage non-small-cell lung cancer. Evidence…”
Get full text

Developments in radiation techniques for thoracic malignancies by Finazzi, Tobias, Schneiders, Famke L, Senan, Suresh

“…Radiation therapy is a cornerstone of modern lung cancer treatment alongside surgery, chemotherapy, immunotherapy and targeted therapies. Advances in…”
Get full text

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial by Palma, David A, Olson, Robert, Harrow, Stephen, Correa, Rohann J M, Schneiders, Famke, Haasbeek, Cornelis J A, Rodrigues, George B, Lock, Michael, Yaremko, Brian P, Bauman, Glenn S, Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V, Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J, de Gruijl, Tanja D, Allan, Alison, Senan, Suresh

“…Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose,…”
Get full text

Tumor volume changes during stereotactic ablative radiotherapy for adrenal gland metastases under MRI guidance by Giraud, Nicolas, Schneiders, Famke L., van Sornsen de Koste, John R., Palacios, Miguel A., Senan, Suresh

“…•Interfraction changes in the GTV of adrenal metastases during 5-fraction SABR delivery exceeded 20% when compared to simulation plans in 59% of treated…”
Get full text

Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial by Olson, Robert, Mathews, Lindsay, Liu, Mitchell, Schellenberg, Devin, Mou, Benjamin, Berrang, Tanya, Harrow, Stephen, Correa, Rohann J M, Bhat, Vasudeva, Pai, Howard, Mohamed, Islam, Miller, Stacy, Schneiders, Famke, Laba, Joanna, Wilke, Derek, Senthi, Sashendra, Louie, Alexander V, Swaminath, Anand, Chalmers, Anthony, Gaede, Stewart, Warner, Andrew, de Gruijl, Tanja D, Allan, Alison, Palma, David A

“…A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease…”
Get full text

Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors by Tekatli, Hilâl, Bohoudi, Omar, Hardcastle, Nicholas, Palacios, Miguel A., Schneiders, Famke L., Bruynzeel, Anna M.E., Siva, Shankar, Senan, Suresh

“…•Central lung SABR is associated with high rates of severe bronchial toxicity. Reliable tolerance doses for the central airways are lacking.•This study…”
Get full text

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy by Tekatli, H., Palacios, M.A., Schneiders, F.L., Haasbeek, C.J., Slotman, B.J., Lagerwaard, F.J., Senan, S.

“…•Delivery of single-fraction SABR to lung tumors on a 0.35T MR-linac resulted in a 3-year local control rate of 97%.•Only 1 patient (2%) developed grade ≥3…”
Get full text

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial by Dickhoff, Chris, Senan, Suresh, Schneiders, Famke L, Veltman, Joris, Hashemi, Sayed, Daniels, Johannes M A, Fransen, Marieke, Heineman, David J, Radonic, Teodora, van de Ven, Peter M, Bartelink, Imke H, Meijboom, Lilian J, Garcia-Vallejo, Juan J, Oprea-Lager, Daniela E, de Gruijl, Tanja D, Bahce, Idris

“…The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due…”
Get full text

Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing by van der Pol, Ymke, Tantyo, Normastuti Adhini, Evander, Nils, Hentschel, Anouk E, Wever, Birgit MM, Ramaker, Jip, Bootsma, Sanne, Fransen, Marieke F, Lenos, Kristiaan J, Vermeulen, Louis, Schneiders, Famke L, Bahce, Idris, Nieuwenhuijzen, Jakko A, Steenbergen, Renske DM, Pegtel, D Michiel, Moldovan, Norbert, Mouliere, Florent

“…Cell‐free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short‐read sequencing lacks deployability and…”
Get full text

Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy by Chen, Hanbo, Schneiders, Famke L., Bruynzeel, Anna M.E., Lagerwaard, Frank J., van Sörnsen de Koste, John R., Cobussen, Paul, Bohoudi, Omar, Slotman, Berend J., Louie, Alexander V., Senan, Suresh

“…•MR-guided adaptive adrenal SABR reduces the chance of stomach toxicity.•Reduction in predicted stomach toxicity was mainly for left adrenal lesions.•Consider…”
Get full text

Bispecific antibody platforms for cancer immunotherapy by Lameris, Roeland, de Bruin, Renée C.G, Schneiders, Famke L, van Bergen en Henegouwen, Paul M.P, Verheul, Henk M.W, de Gruijl, Tanja D, van der Vliet, Hans J

“…Abstract Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody…”
Get full text

Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period by van Vliet, Claire, Dickhoff, Chris, Bahce, Idris, Engelsman, Anton F., Hashemi, Sayed M.S., Haasbeek, Cornelis J.A., Bruynzeel, Anna M.E., Palacios, Miguel A., Becker-Commissaris, Annemarie, Slotman, Berend J., Senan, Suresh, Schneiders, Famke L.

“…We studied treatment patterns for adrenal metastases using surgery or SABR at a single institution during a 10-year period. The number of patients undergoing…”
Get full text

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells by de Bruin, Renée C. G., Veluchamy, John P., Lougheed, Sinéad M., Schneiders, Famke L., Lopez-Lastra, Silvia, Lameris, Roeland, Stam, Anita G., Sebestyen, Zsolt, Kuball, Jürgen, Molthoff, Carla F. M., Hooijberg, Erik, Roovers, Rob C., Santo, James P. Di, van Bergen en Henegouwen, Paul M. P., Verheul, Henk M. W., de Gruijl, Tanja D., van der Vliet, Hans J.

“…Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and…”
Get full text

Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases by van Sörnsen de Koste, John R., Palacios, Miguel A., Chen, Hanbo, Schneiders, Famke L., Bruynzeel, Anna M.E., Slotman, Berend J., Haasbeek, Cornelis J.A., Senan, Suresh

“…•Delivery of breath-hold MR-guided SABR is time-consuming.•Single plane tumor-tracking may fail to detect out-of-plane displacements of organs-at-risk.•Gastric…”
Get full text

Same-day consultation, simulation and lung Stereotactic Ablative Radiotherapy delivery on a Magnetic Resonance-linac by Palacios, Miguel A., Verheijen, Sonja, Schneiders, Famke L., Bohoudi, Omar, Slotman, Berend J., Lagerwaard, Frank J., Senan, Suresh

“…•A same-day consultation and lung SABR workflow was introduced, and experience in 10 patients reported.•A detailed simulation procedure and the use of…”
Get full text

Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk by Schneiders, Famke L., van Vliet, Claire, Giraud, Nicolas, Bruynzeel, Anna M.E., Slotman, Ben J., Palacios, Miguel A., Senan, Suresh

“…•Daily adaptive adrenal SABR in ≤5 fractions is well tolerated, even in patients receiving systemic therapies.•PTV underdosage was reflected by a coverage…”
Get full text

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol by Palma, David A, Giuliani, Meredith E, Correa, Rohann J M, Schneiders, Famke L, Harrow, Stephen, Guckenberger, Matthias, Zhang, Tina, Bahig, Houda, Senthi, Sashendra, Chung, Peter, Olson, Robert, Lock, Michael, Raman, Srinivas, Bauman, Glenn S, Lok, Benjamin H, Laba, Joanna M, Glicksman, Rachel M, Nguyen, Timothy K, Lang, Pencilla, Helou, Joelle, Goodman, Christopher D, Mendez, Lucas C, van Rossum, Peter S N, Warner, Andrew, Gaede, Stewart, Allan, Alison L

“…Emerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as…”
Get full text

Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer by Sanborn, Rachel E, Schneiders, Famke L, Senan, Suresh, Gadgeel, Shirish M

“…The introduction of immune checkpoint inhibitors has dramatically changed the treatment landscape and improved survival for many patients with thoracic…”
Get more information

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study by Bahce, Idris, Dickhoff, Chris, Schneiders, Famke L, Veltman, Joris, Heineman, David J, Hashemi, Sayed M S, Vrijmoet, Anne, Houda, Ilias, Ulas, Ezgi B, Bakker, Joyce, van de Ven, Peter, Bouwhuis, Natalja, Meijboom, Lilian J, Oprea-Lager, Daniela E, van Maldegem, Febe, Fransen, Marieke F, de Gruijl, Tanja D, Radonic, Teodora, Senan, Suresh

“…BackgroundIn non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We…”
Get full text